French Drug Exports Up 18% In 1995

19 May 1996

France's drug industry association, the SNIP, reports that its members' exports of drug specialties in 1995 rose 18% to 25 billion French francs ($4.8 billion), with the commercial balance topping 10 billion francs. Exports to emerging central and eastern European countries, and to Asia and the USA, rose 22%.

Overall drug consumption picked up, after domestic growth in 1994 of only 2.6% and a 10.5% rise in exports. Consumption remained tightly constrained by government reform policies, although pressure on the drug sector was less intense than in 1993-94. The SNIP also says prescribing guidelines had a markedly reduced impact last year; the first phase of the guidelines was introduced in January 1994.

French View Euro P-I Decision Meantime, the SNIP says the European Commission's rejection of requests for safeguards from 10 European Union member states following the opening of the EU market to Spanish drug imports (Marketletter May 13) is "seen as a very negative signal by the drug industry."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight